fda vertex pharmaceuticals - Search News

Vertex Pharma drops

The Boston Globe · 3h

Vertex’s non-opioid pain drug gets some UnitedHealth coverage

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Seeking Alpha on MSN · 5h

Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two commercial formularies.

BioPharma Dive · 42m

Vertex’s new pain drug gets first coverage nod from major insurer

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an interim decision while a formal review continues.

Markets Insider · 4h

Vertex non-opioid pain drug picked up by UnitedHealth

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said,

BioSpace · 10d

Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.

BioPharma Dive9h

Tris to ask for approval of dual-acting pain drug

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Fierce Biotech11h

Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

10h

Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

2h

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

The stock's fall snapped a four-day winning streak.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results